The method of claim 1, wherein the TNF-α inhibitor is CDP-(Amended) 18. 870 and is administered in a dosage of about 1 mg/kg to about 50 mg/kg body weight of said subject. A pharmaceutical composition for treating nerve disorders in 20. (Amended) a subject comprising a therapeutically effective amount of a TNF-α inhibitor wherein said TNF-α inhibitor is CDP-870, and a pharmaceutically acceptable carrier, and wherein said pharmaceutical composition inhibits nerve injury when administered to said subject. The pharmaceutical composition of claim 20, wherein the (Amended) 25. TNF-α inhibitor is CDP-870 in an amount of about 1.0 mg/kg to about 50 mg/kg body BA weight of said subject.

400